DiaMedica Receives FDA Written Response About The Need For Additional Nonclinical Reproductive Toxicity Data To Support Continued Development Of DM199 For The Treatment Of Preeclampsia

Loading news article.

DiaMedica Receives FDA Written Response About The Need For Additional Nonclinical Reproductive Toxicity Data To Support Continued Development Of DM199 For The Treatment Of Preeclampsia | WAPE

DiaMedica Receives FDA Written Response About The Need For Additional Nonclinical Reproductive Toxicity Data To Support Continued Development Of DM199 For The Treatment Of Preeclampsia

Article summary

Related companies

Comments —